Clinical Trial Update: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE [Phase 3]

View source ↗

Summary

A Phase 3 study comparing Abelacimab to dalteparin for cancer-associated venous thromboembolism in gastrointestinal/genitourinary cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Venous Thrombosis
• Gastrointestinal Cancer
• Genitourinary Cancer
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Dalteparin (dalteparin)
• abeLacimab (abeLacimab)

Snippet

Sponsor: Anthos Therapeutics, Inc. | Conditions: Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Status: TERMINATED